Sara S Bashraheel1, Alexander Domling2, Sayed K Goda3. 1. Protein Engineering Unit, Life and Science Research Department, Anti-Doping Lab-Qatar (ADLQ), Doha, Qatar; Drug Design Group, Department of Pharmacy, University of Groningen, Groningen, Netherlands. 2. Drug Design Group, Department of Pharmacy, University of Groningen, Groningen, Netherlands. 3. Cairo University, Faculty of Science, Chemistry Department, Giza, Egypt. Electronic address: sgoda@sci.cu.edu.eg.
Abstract
BACKGROUND: Until recently, patients who have the same type and stage of cancer all receive the same treatment. It has been established, however, that individuals with the same disease respond differently to the same therapy. Further, each tumor undergoes genetic changes that cause cancer to grow and metastasize. The changes that occur in one person's cancer may not occur in others with the same cancer type. These differences also lead to different responses to treatment. Precision medicine, also known as personalized medicine, is a strategy that allows the selection of a treatment based on the patient's genetic makeup. In the case of cancer, the treatment is tailored to take into account the genetic changes that may occur in an individual's tumor. Precision medicine, therefore, could be defined in terms of the targets involved in targeted therapy. METHODS: A literature search in electronic data bases using keywords "cancer targeted therapy, personalized medicine and cancer combination therapies" was conducted to include papers from 2010 to June 2019. RESULTS: Recent developments in strategies of targeted cancer therapy were reported. Specifically, on the two types of targeted therapy; first, immune-based therapy such as the use of immune checkpoint inhibitors (ICIs), immune cytokines, tumor-targeted superantigens (TTS) and ligand targeted therapeutics (LTTs). The second strategy deals with enzyme/small molecules-based therapies, such as the use of a proteolysis targeting chimera (PROTAC), antibody-drug conjugates (ADC) and antibody-directed enzyme prodrug therapy (ADEPT). The precise targeting of the drug to the gene or protein under attack was also investigated, in other words, how precision medicine can be used to tailor treatments. CONCLUSION: The conventional therapeutic paradigm for cancer and other diseases has focused on a single type of intervention for all patients. However, a large literature in oncology supports the therapeutic benefits of a precision medicine approach to therapy as well as combination therapies.
BACKGROUND: Until recently, patients who have the same type and stage of cancer all receive the same treatment. It has been established, however, that individuals with the same disease respond differently to the same therapy. Further, each tumor undergoes genetic changes that cause cancer to grow and metastasize. The changes that occur in one person's cancer may not occur in others with the same cancer type. These differences also lead to different responses to treatment. Precision medicine, also known as personalized medicine, is a strategy that allows the selection of a treatment based on the patient's genetic makeup. In the case of cancer, the treatment is tailored to take into account the genetic changes that may occur in an individual's tumor. Precision medicine, therefore, could be defined in terms of the targets involved in targeted therapy. METHODS: A literature search in electronic data bases using keywords "cancer targeted therapy, personalized medicine and cancer combination therapies" was conducted to include papers from 2010 to June 2019. RESULTS: Recent developments in strategies of targeted cancer therapy were reported. Specifically, on the two types of targeted therapy; first, immune-based therapy such as the use of immune checkpoint inhibitors (ICIs), immune cytokines, tumor-targeted superantigens (TTS) and ligand targeted therapeutics (LTTs). The second strategy deals with enzyme/small molecules-based therapies, such as the use of a proteolysis targeting chimera (PROTAC), antibody-drug conjugates (ADC) and antibody-directed enzyme prodrug therapy (ADEPT). The precise targeting of the drug to the gene or protein under attack was also investigated, in other words, how precision medicine can be used to tailor treatments. CONCLUSION: The conventional therapeutic paradigm for cancer and other diseases has focused on a single type of intervention for all patients. However, a large literature in oncology supports the therapeutic benefits of a precision medicine approach to therapy as well as combination therapies.
Authors: Asim V Farooq; Simona Degli Esposti; Rakesh Popat; Praneetha Thulasi; Sagar Lonial; Ajay K Nooka; Andrzej Jakubowiak; Douglas Sborov; Brian E Zaugg; Ashraf Z Badros; Bennie H Jeng; Natalie S Callander; Joanna Opalinska; January Baron; Trisha Piontek; Julie Byrne; Ira Gupta; Kathryn Colby Journal: Ophthalmol Ther Date: 2020-07-25
Authors: Ali Khader; Rozan Bokhari; Reza Hakimelahi; Christopher Scheirey; Jalil Afnan; Marta Braschi-Amirfarzan; Richard Thomas Journal: Eur J Radiol Open Date: 2022-03-02
Authors: Monica Benvenuto; Sara Ciuffa; Chiara Focaccetti; Diego Sbardella; Sara Fazi; Manuel Scimeca; Grazia Raffaella Tundo; Giovanni Barillari; Maria Segni; Elena Bonanno; Vittorio Manzari; Andrea Modesti; Laura Masuelli; Massimo Coletta; Roberto Bei Journal: Sci Rep Date: 2021-09-24 Impact factor: 4.379